AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34556408 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher waist circumference and urine albumin creatinine (UACR) levels
Number of subjects: 5047
Study 34556565 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF neurogranin
Number of subjects: 0
Study 34556565 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF SNAP-25
Number of subjects: 0
Study 34556565 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF synaptic biomarkers
Number of subjects: 0
Study 34556649 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted reproductive technologies (ART)
Number of subjects: 1178
Study 34556649 — intervention group
Group type: COMPARATOR
Intervention: Spontaneously-conceived singletons
Number of subjects: 1178
Study 34556774 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic measures (school closures, social distancing)
Number of subjects: 150000
Study 34556774 — intervention group
Group type: COMPARATOR
Intervention: Pre-pandemic period (2005-2019)
Number of subjects: 150000
Study 34557402 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment in phase 3 randomized trial NHL-001 (NCT01852435)
Number of subjects: 289
Study 34557558 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy
Number of subjects: 0
Study 34557558 — intervention group
Group type: COMPARATOR
Intervention: COVID-19-specific monoclonal antibody therapy
Number of subjects: 0
Study 34557563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir + rilpivirine LA Q8W
Number of subjects: 274
Study 34557563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir + rilpivirine LA Q4W
Number of subjects: 274
Study 34557563 — intervention group
Group type: COMPARATOR
Intervention: Oral ART
Number of subjects: 274
Study 34557664 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-appearing white matter abnormalities in brain areas where multiple sclerosis lesions subsequently form
Number of subjects: 0
Study 34558001 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical grade human neural stem cells (NSCs) produced following good manufacturing practice guidelines.
Number of subjects: 0
Study 34558001 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols for the production and characterization of clinical grade human neural stem cell lines.
Number of subjects: 0
Study 34558040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤ 24 months
Number of subjects: 99
Study 34558040 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 99
Study 34558059 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic REG3A levels
Number of subjects: 42
Study 34558795 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal RBC Se levels (measured within 72 hours of delivery)
Number of subjects: 1550
Study 34558844 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired cognition (NCT ≥ 45 seconds)
Number of subjects: 1623
Study 34558844 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty (LFI ≥ 4.4)
Number of subjects: 1623
Study 34558844 — intervention group
Group type: EXPERIMENTAL
Intervention: NCT (every 10-second increase)
Number of subjects: 1623
Study 34558844 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 1623
Study 34558844 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired cognition
Number of subjects: 1623
Study 34558844 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty (after adjustment)
Number of subjects: 1623
Study 34558844 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired cognition mediation
Number of subjects: 1623
Study 34558866 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic liver injury (HLI) in the ER
Number of subjects: 1537
Study 34558866 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic hepatitis (HH)
Number of subjects: 1537
Study 34558866 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no HLI or HH)
Number of subjects: 1537
Study 34558866 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (HLI, but no HH)
Number of subjects: 1537
Study 34558866 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (no HLI, but HH)
Number of subjects: 1537
Study 34558866 — intervention group
Group type: COMPARATOR
Intervention: Group 4 (both HLI and HH)
Number of subjects: 1537
Study 34558866 — intervention group
Group type: EXPERIMENTAL
Intervention: HLI in the ER
Number of subjects: 1537
Study 34558884 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Number of subjects: 136
Study 34558884 — intervention group
Group type: COMPARATOR
Intervention: Disability insurance (DIR)
Number of subjects: 136
Study 34558884 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability insurance allowance
Number of subjects: 136
Study 34559006 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body MRI
Number of subjects: 0
Study 34559006 — intervention group
Group type: COMPARATOR
Intervention: FDG PET/CT
Number of subjects: 0
Study 34559026 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange sex behavior (selling and purchasing)
Number of subjects: 0
Study 34559026 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of sexual partners
Number of subjects: 0
Study 34559026 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about contracting HIV/AIDS
Number of subjects: 0
Study 34559026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative interpersonal trauma exposure
Number of subjects: 0
Study 34559026 — intervention group
Group type: EXPERIMENTAL
Intervention: Years using cocaine
Number of subjects: 0
Study 34559026 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related problem days
Number of subjects: 0
Study 34559026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual preference
Number of subjects: 0
Study 34559032 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Distress Scale (DD Scale)
Number of subjects: 15
Study 34559032 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic analysis
Number of subjects: 15
Study 34559353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Number of subjects: 325
Study 34559353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 34559354 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral complementary and alternative medicine (OCAM) use
Number of subjects: 5237
Study 34559354 — intervention group
Group type: EXPERIMENTAL
Intervention: OCAM use at diagnosis
Number of subjects: 5237
Study 34559354 — intervention group
Group type: EXPERIMENTAL
Intervention: OCAM use post-diagnosis
Number of subjects: 5237
Study 34559360 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib + cisplatin
Number of subjects: 115
Study 34559360 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib + cetuximab
Number of subjects: 115
Study 34559360 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib + 5-fluorouracil
Number of subjects: 115
Study 34559360 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib + pemetrexed
Number of subjects: 115
Study 34559360 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib combinations
Number of subjects: 115
Study 34559362 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Spectroscopy (EIS)
Number of subjects: 60
Study 34559362 — intervention group
Group type: COMPARATOR
Intervention: Targeted biopsies (current diagnostic standard)
Number of subjects: 60
Study 34559670 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided digital problem-solving intervention for 1 week
Number of subjects: 396
Study 34559670 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment regarding symptoms of depression and anxiety prior to intervention
Number of subjects: 396
Study 34559670 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed 13-item inventory based on problem categories derived from content analysis
Number of subjects: 396
Study 34559851 — intervention group
Group type: EXPERIMENTAL
Intervention: CBE Intervention (6 months): aerobic, strength, balance and flexibility training for 90 minutes, 3 times/week, with weekly supervised coaching.
Number of subjects: 108
Study 34559851 — intervention group
Group type: EXPERIMENTAL
Intervention: CBE Intervention (6 months)
Number of subjects: 108
Study 34559851 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 3 follow-up
Number of subjects: 108
Study 34559884 — intervention group
Group type: EXPERIMENTAL
Intervention: Any type of forceps
Number of subjects: 5754
Study 34559884 — intervention group
Group type: COMPARATOR
Intervention: Low-cavity forceps
Number of subjects: 5754
Study 34559884 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft vacuum cup
Number of subjects: 5754
Study 34559884 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld vacuum
Number of subjects: 5754
Study 34559944 — intervention group
Group type: EXPERIMENTAL
Intervention: HKTP intervention at Site A
Number of subjects: 2063
Study 34559944 — intervention group
Group type: EXPERIMENTAL
Intervention: HKTP intervention at Site B
Number of subjects: 2063
Study 34559944 — intervention group
Group type: COMPARATOR
Intervention: Control Site C
Number of subjects: 2063
Study 34559944 — intervention group
Group type: COMPARATOR
Intervention: Control Site D
Number of subjects: 2063
Study 34560047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole treatment
Number of subjects: 28
Study 34560607 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten intake (highest tertile)
Number of subjects: 147
Study 34560607 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten intake (lowest tertile)
Number of subjects: 147
Study 34560607 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten intake (intermediate tertile)
Number of subjects: 147
Study 34560607 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake (highest tertile of gluten)
Number of subjects: 147
Study 34560607 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake (lowest tertile of gluten)
Number of subjects: 147
Study 34560607 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake (intermediate tertile of gluten)
Number of subjects: 147
Study 34560607 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructan intake
Number of subjects: 147
Study 34560789 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (3 days/week)
Number of subjects: 178
Study 34560843 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model including multiparity, pre-pregnancy BMI, and PAPP-A MoM
Number of subjects: 503
Study 34560853 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in HIV consultation and testing
Number of subjects: 426
Study 34560853 — intervention group
Group type: EXPERIMENTAL
Intervention: General health checks
Number of subjects: 426
Study 34560853 — intervention group
Group type: EXPERIMENTAL
Intervention: Online health toolkit
Number of subjects: 426
Study 34560853 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention (Test@Work)
Number of subjects: 426
Study 34560876 — intervention group
Group type: EXPERIMENTAL
Intervention: aHGL in MIOCA
Number of subjects: 2431
Study 34560876 — intervention group
Group type: EXPERIMENTAL
Intervention: aHGL in MINOCA
Number of subjects: 2431
Study 34560876 — intervention group
Group type: COMPARATOR
Intervention: no-aHGL in MIOCA
Number of subjects: 2431
Study 34560876 — intervention group
Group type: COMPARATOR
Intervention: no-aHGL in MINOCA
Number of subjects: 2431
Study 34560876 — intervention group
Group type: EXPERIMENTAL
Intervention: aHGL
Number of subjects: 2431
Study 34560906 — intervention group
Group type: COMPARATOR
Intervention: Ixekizumab every 4 weeks
Number of subjects: 0
Study 34560906 — intervention group
Group type: COMPARATOR
Intervention: Ixekizumab every 2 weeks
Number of subjects: 0
Study 34560906 — intervention group
Group type: COMPARATOR
Intervention: Ixekizumab (both dosing regimens)
Number of subjects: 0
Study 34561039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracentral Lung Stereotactic Ablative Radiotherapy
Number of subjects: 0
Study 34561039 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34561255 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary patient-centred care intervention
Number of subjects: 29
Study 34561254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 148
Study 34561254 — intervention group
Group type: COMPARATOR
Intervention: Routine diagnostic procedure
Number of subjects: 148
Study 34561254 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS
Number of subjects: 148
Study 34561258 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for identifying NSCLC
Number of subjects: 314
Study 34561256 — intervention group
Group type: EXPERIMENTAL
Intervention: Bespoke ctDNA testing
Number of subjects: 2000
Study 34561256 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 2000
Study 34561256 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD clearance rate
Number of subjects: 2000
Study 34561256 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for oligometastatic recurrence
Number of subjects: 2000
Study 34561256 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 2000
Study 34561256 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of recurrent disease
Number of subjects: 2000
Study 34561256 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 2000
Study 34561289 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34561293 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA prescriptions (≥3 canisters)
Number of subjects: 8351
Study 34561293 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC SABA purchases
Number of subjects: 8351
Study 34561293 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA prescriptions (3-5, 6-9, 10-12, ≥13 canisters)
Number of subjects: 8351
Study 34561380 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made insoles and exercise program
Number of subjects: 40
Study 34561387 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodstream infections (BSIs)
Number of subjects: 5433
Study 34561387 — intervention group
Group type: EXPERIMENTAL
Intervention: Klebsiella pneumoniae
Number of subjects: 5433
Study 34561387 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 5433
Study 34561548 — intervention group
Group type: EXPERIMENTAL
Intervention: SRK/T formula
Number of subjects: 80
Study 34561548 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrett Universal II formula
Number of subjects: 80
Study 34561548 — intervention group
Group type: EXPERIMENTAL
Intervention: Hill-RBF formula
Number of subjects: 80
Study 34561548 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 34561712 — intervention group
Group type: EXPERIMENTAL
Intervention: VACStent®
Number of subjects: 20
Study 34561812 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin (2.5 mg/kg)
Number of subjects: 220
Study 34561812 — intervention group
Group type: COMPARATOR
Intervention: Selinexor plus dexamethasone (80 mg + 20 mg)
Number of subjects: 220
Study 34562096 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS with vorinostat (VOR)
Number of subjects: 8
Study 34562103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp-PLA2 inhibitor
Number of subjects: 0
Study 34562103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34562103 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Lp-PLA2 activity (Q4)
Number of subjects: 0
Study 34562103 — intervention group
Group type: EXPERIMENTAL
Intervention: High Lp-PLA2 activity (Q4)
Number of subjects: 0
Study 34562103 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Lp-PLA2 activity (Q1-3)
Number of subjects: 0
Study 34562149 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (1.0 g/dL) administered intravenously at a priming rate of 8 mL/kg/hr for 30 min, followed by a maintenance rate of 0.7 × eGFR mL/min/1.73 m².
Number of subjects: 60
Study 34562149 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (1.0 g/dL) administered intravenously.
Number of subjects: 60
Study 34562193 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered flavor test (four solutions: coffee, peppermint, banana)
Number of subjects: 111
Study 34562193 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reporting questionnaire on smell and flavor perception
Number of subjects: 111
Study 34562193 — intervention group
Group type: COMPARATOR
Intervention: Self-administered flavor test
Number of subjects: 111
Study 34562230 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg QW in combination with carboplatin and paclitaxel (CT)
Number of subjects: 13
Study 34562230 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (CT)
Number of subjects: 13
Study 34562231 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (900U)
Number of subjects: 0
Study 34562231 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA (360U)
Number of subjects: 0
Study 34562231 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Number of subjects: 0
Study 34562231 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA
Number of subjects: 0
Study 34562237 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide
Number of subjects: 0
Study 34562237 — intervention group
Group type: COMPARATOR
Intervention: Comparators (not specified)
Number of subjects: 0
Study 34562313 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg orally twice daily for 6 months
Number of subjects: 16
Study 34562489 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (3 mL) + Lidocaine 2% (3 mL) + Hyaluronidase 150 IU (1 mL), initial volume 7 mL, adjusted based on previous patient response.
Number of subjects: 119
Study 34563161 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommender system with motivational messages sent every 3 days, incorporating user feedback on a 5-point Likert scale.
Number of subjects: 731
Study 34563161 — intervention group
Group type: EXPERIMENTAL
Intervention: High user-system engagement through the recommender system.
Number of subjects: 731
Study 34563240 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter treatment regimens containing new drugs (39-week multi-drug regimens)
Number of subjects: 750
Study 34563240 — intervention group
Group type: COMPARATOR
Intervention: Control arm based on the current standard of care for MDR/RR-TB
Number of subjects: 750
Study 34563397 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccine
Number of subjects: 206
Study 34563670 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 2504
Study 34563730 — intervention group
Group type: EXPERIMENTAL
Intervention: Human amniotic membrane (HAM) transplantation after sequestrectomy
Number of subjects: 5
Study 34563744 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 0
Study 34563744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 0
Study 34563914 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month pelvic floor muscle training programme (one group session per month)
Number of subjects: 141
Study 34563917 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed strength and cardiovascular exercise intervention pre-ASCT
Number of subjects: 23
Study 34563945 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat (4 mg, 6 mg, or 8 mg orally on days 1 and 8) plus Clofarabine (10 mg/m2)
Number of subjects: 28
Study 34564001 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Control Assessment of the Lower Extremity (SCALE)
Number of subjects: 42
Study 34564048 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid bulb IMT in men with CoA
Number of subjects: 64
Study 34564048 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid artery (CCA) IMT in men with CoA
Number of subjects: 64
Study 34564048 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid artery (CCA) IMT in women with CoA
Number of subjects: 64
Study 34564048 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque presence in carotid arteries in men with CoA
Number of subjects: 64
Study 34564048 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell factor (SCF) levels in women with CoA
Number of subjects: 64
Study 34564048 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix metalloproteinase-3 (MMP-3) levels in men with CoA
Number of subjects: 64
Study 34564048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor receptor 1 (TNF-R1) levels in men with CoA
Number of subjects: 64
Study 34564048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor receptor superfamily member 10B (TRAIL-R2) levels in men with CoA
Number of subjects: 64
Study 34564048 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte chemotactic protein 1 (MCP-1) levels in men with CoA
Number of subjects: 64
Study 34564131 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with a Medtronic valve
Number of subjects: 3821
Study 34564355 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to airborne unintentionally released nanoparticles
Number of subjects: 100
Study 34564355 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic pulmonary fibrosis
Number of subjects: 100
Study 34564355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcoidosis
Number of subjects: 100
Study 34564694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg days 1-10 of each cycle plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for six cycles
Number of subjects: 39
Study 34564694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg days 1-10 of each cycle plus R-CHOP
Number of subjects: 39
Study 34564780 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydro-mechanical defragmentation (HMD)
Number of subjects: 50
Study 34564780 — intervention group
Group type: COMPARATOR
Intervention: Systemic thrombolysis (ST)
Number of subjects: 50
Study 34564842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 0
Study 34564842 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0